| 摘要 |
The invention relates to intermittent administration of a levosimendan compound or a pharmaceutically acceptable salt thereof in the treatment of cardiovascular disorders such as chronic heart failure. The intermittent dose is more than 0.04 mg/kg and the period between each intermittent dose is 6-30 days, preferably 6-25 days. The administration is suitably, for example, an intermittent intravenous infusion.
|
